Website profile

Clinical Trials Arena

Hard data and deep insights on clinical trials strategy & operations

  • 213articles · 90d
  • 2+ day agolatest article
  • Jun 15, 2026earliest in window
  • 92%with images
  • 322avg words
articles per day
Categories
  • Medical 207
  • Health & Wellness 197
  • Health 154
  • Science & Technology 30
  • Economy, Business & Finance 26
  • Business & Industrial 13
  • Finance & Business 3
  • Science & Nature 2

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Google News
clinicaltrialsarena.com > news > veradermics-stock-jumps-again-on-female-hair-loss-drug-win

Veradermics stock jumps again on female hair loss drug win

1+ mon, 3+ week ago   (506+ words) This is the second positive Phase II readout of VDPHL01, which analysts note could represent a $2bn+ market opportunity Veradermics has seen another jump in its stock price as its hair loss drug showed benefit in women with androgenetic alopecia (AGA). Patients…...

Clinical Trials Arena
clinicaltrialsarena.com > news > q32-bio-36-week-data-signal-aa-trials

Q32 Bio reports 36-week data from SIGNAL-AA trial’s Part B in alopecia areata

1+ mon, 4+ week ago   (394+ words) Q32 Bio has reported positive 36-week top line data from Part B of the SIGNAL-AA Phase IIa trial of bempikibart for patients with severe or very severe alopecia areata (AA). Bempikibart is a fully human antibody that targets the interleukin-7 receptor…...